Spyre Therapeutics, Inc. (SYRE) FY2025 10-K Annual Report
Spyre Therapeutics, Inc. (SYRE) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 19, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Spyre Therapeutics, Inc. FY2025 10-K Analysis
Business Overview
- • Core business model redesigned as clinical stage biotech focused on next-generation monoclonal antibodies for IBD and immune-mediated diseases
- • Emphasis on half-life extended antibodies aiming for less frequent, self-administered subcutaneous injections
- • Planning combination therapy trials to enhance efficacy beyond monotherapies in IBD
- • Operational risks from macroeconomic factors including inflation, geopolitical tensions, and supply chain disruptions highlighted with uncertain financial impact
- • Early-stage with no selected delivery technology, reflecting ongoing platform development and pipeline innovation
Management Discussion & Analysis
- • No revenue reported in FY 2026, focus on pre-clinical stage asset acquisition and licensing
- • No profitability or margin data provided due to early-stage operations and recent acquisitions
- • Best segment: α4β7 integrin program (SPY001) licensed July 2023 for global therapeutic development
- • Capital allocation details not disclosed; emphasis on exercise of license options and exclusive IP rights acquisition
- • Forward outlook: advancing multiple research programs with exclusive licenses, ongoing option for final program license
Risk Factors
- • Legal risk from increased costs to comply with Nasdaq listing rules and SEC requirements post going public
- • Macroeconomic impact of $2.0M lease termination fee for Austin office abandonment creating liquidity pressure
- • Operational risk from reliance on Paragon and multiple CROs/CMOs for R&D services accruing significant expenses
- • Competitive risk from inconclusive Phase 1/2 trial results for pegtarviliase triggering strategic alternatives process
- • Financial risk from $6.4M restructuring expenses and 83% workforce reduction impacting organizational stability
Spyre Therapeutics, Inc. FY2025 Key Financial MetricsXBRL
Revenue
$0
Net Income
-$155M
▲ +25.4% YoY
ROE
-21.7%
▲ +1847bp YoY
Total Assets
$778M
▲ +27.8% YoY
Operating Cash Flow
-$169M
▼ -7.5% YoY
Source: XBRL data from Spyre Therapeutics, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Spyre Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.